A microbiome-guided diet held its IBS benefit at a year, while low-FODMAP relapsed

The low-FODMAP diet works for irritable bowel syndrome in the short term, and nobody knew what happens after. Followed for 12 months without further support, its gains had gone. A diet built from each person's gut bacteria kept them.

Onions, garlic, ginger and halved oranges arranged on a board against a dark background

Summary

A diet built from a person's own gut bacteria kept its IBS benefit a year later.
The low-FODMAP diet worked just as well at six weeks, then the gains went.
Both groups were left unsupported after six weeks, which is what real life looks like.
Almost twice as many people were still doing well on the personalized diet at a year.
The personalized group also held on to a more varied gut microbiome.

Almost every dietary trial in irritable bowel syndrome stops at six or eight weeks. That is long enough to show a diet works, and short enough to avoid the question everybody with the condition actually asks: and then what?

Writing in Gut Microbes, researchers ran the follow-up. Participants who had completed a 6-week dietary intervention were left alone for a year, with no further dietary support, and measured again at 6 and 12 months.

Both diets reduced IBS-SSS at 6 weeks. Only one of them still had anything to show for it at twelve.

The condition, and why diet is the front line

Irritable bowel syndrome is a problem that affects the large intestine, and it can cause abdominal cramping, bloating, and a change in bowel habits.

It is common, it affects about twice as many women as men, and no one knows the exact cause. There is no test that confirms it and no drug that reliably fixes it, which is why most people diagnosed with IBS can control their symptoms with diet, stress management, probiotics, and medicine, in roughly that order of emphasis.

The low-FODMAP diet is the best-evidenced of those dietary options. It removes fermentable carbohydrates found in wheat, onions, legumes, some fruit and dairy, and short-term trials consistently show it helps.

What happened over the year

The personalized diet maintained symptom improvement at 6 and 12 months, at 82 and 78 points below where people started on the symptom severity score.

The comparison arm did not. Low-FODMAP benefits regressed by 12 months, ending 29 points above baseline, which is to say worse than before the trial began.

The responder figures make the gap concrete. At 12 months, IBS-SSS responder rates were higher with the personalized diet than low-FODMAP, 62.5% against 34.5%, a difference of 28 percentage points.

Quality of life and anxiety and depression scores showed more favourable trajectories with the personalized diet as well.

Why the low-FODMAP result is not a criticism of low-FODMAP

The diet did what it is supposed to do. It reduced symptoms at six weeks, which is what the evidence base has always claimed for it.

What the trial exposes is a design feature nobody talks about: low-FODMAP is meant to be temporary. The protocol is elimination followed by structured reintroduction, guided by a dietitian, so that people end up eating as widely as their symptoms allow rather than avoiding a long list forever.

Take away the dietitian for twelve months and you have people either drifting back to their old diet, or staying on a restriction they were never meant to keep, and this trial cannot tell you which. Either way the benefit went.

That is a finding about how the treatment is delivered as much as about the diet itself.

The bacteria, and the honest limits there

The personalized arm was associated with sustained gains in Shannon alpha-diversity, a measure of how many different bacterial types are present and how evenly they are spread.

Diversity is not automatically good, and the field has a habit of treating it as a scoreboard. What makes it worth noting here is the direction: low-FODMAP diets are known to reduce the bacteria that feed on fermentable fiber, which is a predictable cost of removing that fiber. A personalized approach that subtracts less, and subtracts different things for different people, would be expected to cost less diversity.

The microbiome composition difference between groups was not significant at 12 months, which the authors report rather than bury.

What to do with this

Cautiously, and not by buying a test.

This was a small, open-label trial, and the authors describe it as hypothesis-generating and ask for larger trials powered for long-term clinical and microbiome outcomes. The personalization here was a research protocol, not a product, and the commercial gut-testing industry is not running the same thing.

The transferable lesson is about durability rather than about microbiomes. A dietary treatment for IBS that only works while somebody is supervising it is a partial treatment, and the six-week trials that dominate this field have been systematically unable to see that.

For anyone currently on a low-FODMAP diet, the practical implication is the reintroduction phase: it is the part most often skipped, and this trial is an argument that skipping it costs you the benefit within a year.